Cardiovascular
Iron therapy linked with reduced hospitalisation in iron-deficient heart failure patients
Notes to editor
ESC Press Office
Tel: +336 61 40 18 84
Email: [email protected]
The hashtag for ESC Congress 2023 is #ESCCongress
Follow us on Twitter @ESCardioNews
This press release accompanies both a presentation and an ESC press conference at ESC Congress 2023. It does not necessarily reflect the opinion of the European Society of Cardiology.
Funding: CSL Vifor.
Disclosures: Professor Ponikowski reports research grants, consulting fees, speaker’s bureau for Bayer, MSD, Servier, Novartis, Vifor Pharma Ltd., BMS, Boehringer Ingelheim, Respicardia, AstraZeneca, and Berlin Chemie.
References and notes
1Effects of FCM meta-analysis will be discussed during Hot Line 2 on Saturday 26 August at 08:30 to 10:00 CEST in room Amsterdam.
2Rocha BML, Cunha GJL, Menezes Falcão LF. The burden of iron deficiency in heart failure: therapeutic approach. J Am Coll Cardiol. 2018;71:782-793.
3Ponikowski P, van Veldhuisen DJ, Comin-Colet J, et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J. 2015;36:657-668.
4Anker SD, Comin Colet J, Filippatos G, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med. 2009;361:2436-2448.
About ESC Congress 2023
It is the world’s largest gathering of cardiovascular professionals, disseminating ground-breaking science both onsite in Amsterdam and online – from 25 to 28 August. Explore the scientific programme. More information is available from the ESC Press Office at [email protected].
About the European Society of Cardiology
The ESC brings together health care professionals from more than 150 countries, working to advance cardiovascular medicine and help people to live longer, healthier lives.
